MXPA04007434A - Tratamiento de la disfuncion sexual masculina. - Google Patents

Tratamiento de la disfuncion sexual masculina.

Info

Publication number
MXPA04007434A
MXPA04007434A MXPA04007434A MXPA04007434A MXPA04007434A MX PA04007434 A MXPA04007434 A MX PA04007434A MX PA04007434 A MXPA04007434 A MX PA04007434A MX PA04007434 A MXPA04007434 A MX PA04007434A MX PA04007434 A MXPA04007434 A MX PA04007434A
Authority
MX
Mexico
Prior art keywords
treatment
sexual dysfunction
male sexual
oxytocin antagonist
selective oxytocin
Prior art date
Application number
MXPA04007434A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Peter Wayman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA04007434A publication Critical patent/MXPA04007434A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MXPA04007434A 2002-01-31 2003-01-20 Tratamiento de la disfuncion sexual masculina. MXPA04007434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202282.0A GB0202282D0 (en) 2002-01-31 2002-01-31 Treatment of male sexual dysfunction
PCT/IB2003/000140 WO2003064402A1 (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
MXPA04007434A true MXPA04007434A (es) 2004-10-11

Family

ID=9930155

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04007434A MXPA04007434A (es) 2002-01-31 2003-01-20 Tratamiento de la disfuncion sexual masculina.

Country Status (16)

Country Link
EP (1) EP1470115A1 (pt)
JP (3) JP2005525321A (pt)
KR (2) KR100829262B1 (pt)
CN (1) CN100500658C (pt)
AU (1) AU2003201471B2 (pt)
BR (1) BR0307337A (pt)
CA (1) CA2474590A1 (pt)
GB (1) GB0202282D0 (pt)
HK (1) HK1073109A1 (pt)
IL (2) IL162822A0 (pt)
MX (1) MXPA04007434A (pt)
NZ (1) NZ546408A (pt)
PL (1) PL371415A1 (pt)
TW (1) TW200302732A (pt)
WO (1) WO2003064402A1 (pt)
ZA (1) ZA200405208B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3646871A1 (en) * 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Treatment and prevention of premature ejaculation (pe)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
AU690534B2 (en) * 1992-12-23 1998-04-30 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
CA2118756A1 (en) * 1993-03-12 1994-09-13 Anthony M. Demarco Process for the synthesis of substituted amide derivatives of piperizinylcamphorsulfonyl oxytocin antagonists
GB0007884D0 (en) 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
US20020028799A1 (en) * 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction

Also Published As

Publication number Publication date
HK1073109A1 (en) 2005-09-23
KR100829262B1 (ko) 2008-05-13
CN100500658C (zh) 2009-06-17
EP1470115A1 (en) 2004-10-27
ZA200405208B (en) 2005-08-31
JP2013151511A (ja) 2013-08-08
CN1625553A (zh) 2005-06-08
JP2010209075A (ja) 2010-09-24
WO2003064402A1 (en) 2003-08-07
PL371415A1 (en) 2005-06-13
JP2005525321A (ja) 2005-08-25
GB0202282D0 (en) 2002-03-20
TW200302732A (en) 2003-08-16
IL162822A (en) 2010-11-30
BR0307337A (pt) 2004-12-07
KR20080011232A (ko) 2008-01-31
AU2003201471B2 (en) 2009-03-26
KR20040079958A (ko) 2004-09-16
NZ546408A (en) 2007-10-26
IL162822A0 (en) 2005-11-20
CA2474590A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
SG148202A1 (en) Quinazolinone compounds as anticancer agents
MXPA03010790A (es) Heterociclos biciclicos que contienen nitrogeno para uso como antibacterianos.
UA84141C2 (ru) Применение ингибитора пктжк для лечения или профилактики запора
IL176452A0 (en) Effervescent oral opiate dosage form
MXPA05013142A (es) Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.
AP2001002125A0 (en) Controlled-rease pharmaceutical formulations.
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
GB0101577D0 (en) Compounds
WO2003103603A3 (en) NEW FORMIATE-TYPE SALT OF O-DESMETHYLVENLAFAXINE
MXPA04000586A (es) Combinacion de un atagonista del receptor de aldosterona con un inhibidor de la hmg coa reductasa.
WO2004005324A3 (en) Peptide composition for treatment of sexual dysfunction
WO2004006859A3 (en) Platinum compound
YU89503A (sh) Korišćenje osteopontina za lečenje i/ili prevenciju neuroloških bolesti
MY137620A (en) Therapeutic treatment
MY128896A (en) Pharmaceutical combinations
TW200508199A (en) Novel compound
EP1448194A4 (en) DOSAGE FORM CONTAINING APOMORPHINE FOR IMPROVING MALE DYSERECTION
EP1441718A4 (en) CARBINOL FOR THE TREATMENT OF NEUROPATHIC FUNCTIONAL DISORDER
SI1603584T1 (sl) Aplidin za zdravljenje multiple mieloma
MXPA04007434A (es) Tratamiento de la disfuncion sexual masculina.
MY135441A (en) Therapeutic treatment
IL158762A0 (en) Prevention of addiction in pain management
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
IL166273A0 (en) Methods of treatment of male erectile dysfunction

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights